| |
|
|
|
|
|
 |
| |
|
¸ðµðÁþÁ¤ MODIZID TAB.[Hydrochlorothiazide , Triamterene]
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A14100691]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1T(1996.05.01)(Ãֽžడ)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ¿øÇüÁ¤Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
100T, 250T |
| º¸°ü¹æ¹ý |
±â¹Ð¿ë±â
|
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
- °íÇ÷¾Ð ¹× ¿ïÇ÷¼º ½ÉºÎÀü(Ä¡¾ÆÁþ°è ¶Ç´Â Ä®·ýÀ̿ ¹èÃ⼺ ÀÌ´¢Á¦ ´Üµ¶Åõ¿©½Ã ÀúÄ®·ýÇ÷ÁõÀÌ ³ªÅ¸³ª´Â °æ¿ì)
- Á¤»óÀûÀÎ Ç÷ûĮ·ý ÀÌ¿ÂÄ¡ÀÇ À¯Áö°¡ ÀÓ»óÀûÀ¸·Î Áß¿äÇÑ °æ¿ì(µð±âÅ»¸®½º ¿ä¹ý½Ã ¹× ÁßÁõ½ÉºÎÁ¤¸Æ)
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Chlorothiazide][Hydrochlorothiazide][Triamterene]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
ÀÌ ¾àÀº ½Ä»ç¿Í ÇÔ°è Åõ¿©ÇØ¾ß ÇÑ´Ù. º¸Åë ¼ºÀÎ Ãʱâ 1ÀÏ 1Á¤ °æ±¸Åõ¿©Çϰí ÇÊ¿ä½Ã 1ÀÏ 2Á¤±îÁö Áõ·®ÇÒ ¼ö ÀÖ´Ù.1ÀÏ ¿ë·®Àº 1ȸ Åõ¿©ÇÏ´Â °ÍÀ» ¿øÄ¢À¸·Î Çϳª ºÐÇÒÅõ¿©µµ °¡´ÉÇÏ´Ù.ÀÏ´Ü ÀÌ´¢ÀÛ¿ëÀÌ ³ªÅ¸³ª¸é ¿ë·®Á¶ÀýÀÌ ÇÊ¿äÇÏ´Ù.À¯Áö¿ä¹ýÀº °£ÇæÀûÀ¸·Î ½Ç½ÃÇÑ´Ù.
ÇÕº´ÁõÀÌ ¾ø´Â º»Å¼º °íÇ÷¾ÐÀ¸·Î ÀÌ´¢Á¦¸¦ Åõ¿©Çϰí Àִ ȯÀÚ°¡ Á¤»óÀûÀÎ ½Ä»ç¸¦ ÇÏ´Â °æ¿ì¿¡´Â Ä®·ýº¸Á¸¼º ÀÌ´¢Á¦¸¦ Åõ¿©ÇÒ Çʿ䰡 ¾ø´Ù.
ÀÌ ¾àÀº ´Üµ¶À¸·Î Åõ¿©Çϰųª ¸ÞÄ¥µµÆÄ, B-Â÷´ÜÁ¦¿Í °°Àº ´Ù¸¥ °íÇ÷¾Ð Ä¡·áÁ¦ÀÇ º¸Á¶Á¦·Î »ç¿ëµÉ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ °æ¿ì´Â ÀÌ ¾àÀº ´Ù¸¥ °íÇ÷¾Ð Ä¡·áÁ¦ÀÇ ÀÛ¿ëÀ» Áõ°½ÃŰ¹Ç·Î °ú´ÙÇÑ Ç÷¾Ð°ÇÏ ¶Ç´Â ¹Ù¶÷Á÷ÇÏÁö ¸øÇÑ ºÎÀÛ¿ëÀ» ÇÇÇϱâ À§ÇØ ¿ë·®Á¶ÀýÀÌ ÇÊ¿äÇÏ´Ù.
ÀÌ ¾àÀº ºÎÁ¾ ¶Ç´Â °íÇ÷¾ÐÀÇ Ãʱâ Ä¡·á¿¡ »ç¿ëÇÏÁö ¾Ê´Â´Ù. ´Ù¸¸ ÀúÄ®·ýÇ÷ÁõÀ¸·Î ¹ßÀüµÉ À§Ç輺ÀÌ Àִ ȯÀÚ¿¡´Â »ç¿ëÇÒ¼ö ÀÖ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[º¸±â]
|
| ±Ý±â |
- °úÄ®·ýÇ÷ÁõȯÀÚ(Ç÷û Ä®·ýÄ¡°¡ 5.5mEq/LÀÌ»ó)
- ´Ù¸¥ Ä®·ý º¸Á¸¼º ÀÌ´¢Á¦ ¶Ç´Â Ä®·ý º¸±ÞÀ» ¹Þ´Â ȯÀÚ
- ¹«´¢Áõ, ±Þ¼º ¶Ç´Â ¸¸¼º ½ÅºÎÀü ¹× ´ç´¢º´¼º ½ÅÀ庴°ú °°Àº ½ÅÀå¾Ö°¡ Àִ ȯÀÚ
- ÀÌ ¾à ¶Ç´Â ¼³Æù¾Æ¹Ìµå À¯µµÃ¼ ¾à¹°¿¡ °ú¹Î¼ºÀÌ Àִ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
- ÀÌ ¾àÀº °úÄ®·ýÇ÷ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. °ú Ä®·ýÇ÷ÁõÀº ±³Á¤µÇÁö ¾ÊÀ¸¸é Ä¡¸íÀûÀÏ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀ» óÀ½ ¾²°Å³ª ¿ë·® Á¶ÀýÀ» ÇÒ °æ¿ì ¶Ç´Â ½Å±â´É¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ÁúȯÀÌ Àִ ȯÀÚ¿¡´Â Ç÷û Ä®·ýÄ¡¸¦ °üÂûÇØ¾ß ÇÑ´Ù.
- ´ç´¢º´È¯ÀÚ, ´ç´¢º´¼º ½ÅÀ庴ÀÇ °¡´É¼ºÀÌ Àִ ȯÀÚÀÇ °æ¿ì °¡´ÉÇÑ ÇÑ ±× »ç¿ëÀ» ÇÇÇØ¾ß Çϸç ÀÌ ¾àÀ» Åõ¿©ÇÒ °æ¿ì¿¡´Â Ç÷û ÀüÇØÁú°ú ½Å±â´ÉÀ» ÀÚÁÖ °üÂûÇØ¾ß ÇÑ´Ù. Àû¾îµµ ´ç³»¼º°Ë»ç 3ÀÏÀü¿¡´Â ÀÌ ¾àÀÇ Åõ¿©¸¦ ÁßÁöÇØ¾ß ÇÑ´Ù.
|
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
±â¹Ð¿ë±â
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Dµî±Þ
(Àӽżº °íÇ÷¾Ð¿¡ Åõ¿©½Ã )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Hydrochlorothiazide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ As a diuretic, hydrochlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like hydrochlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of hydrochlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Triamterene¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Triamterene interferes with sodium reabsorption in the distal renal tubule by inhibiting sodium transport mechanisms directly. Specifically it inhibits the Na+/K+/2Cl- co-transporter. The result is an electrical-potential difference across the membrane that blocks the passive distal tubular secretion of potassium. Relative to other diuretics, triamterene has a unique mode of action as it inhibits the reabsorption of sodium ions in exchange for potassium and hydrogen ions at that segment of the distal tubule under the control of adrenal mineralocorticoids (especially aldosterone).
|
| Pharmacology |
Hydrochlorothiazide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Thiazides such as hydrochlorothiazide promote water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Triamterene¿¡ ´ëÇÑ Pharmacology Á¤º¸ Triamterene, a relatively weak, potassium-sparing distal tubule diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium.
|
| Metabolism |
Hydrochlorothiazide¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Hydrochlorothiazide¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 67.9%
Triamterene¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 97%
|
| Half-life |
Hydrochlorothiazide¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 5.6 and 14.8 hours
|
| Absorption |
Hydrochlorothiazide¿¡ ´ëÇÑ Absorption Á¤º¸ 50-60%
Triamterene¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.
|
| Pharmacokinetics |
TriamtereneÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 2-4 ½Ã°£ À̳»¿¡ ÀÌ´¢È¿°ú°¡ ³ªÅ¸³´Ù.
- ÀÛ¿ëÁö¼Ó½Ã°£ : 7-9 ½Ã°£
- Èí¼ö : °æ±¸ : °³Ã¼Â÷°¡ Å©´Ù.
HydrochlorothiazideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÌ´¢È¿°ú ¹ßÇö½Ã°£ : °æ±¸ : 2½Ã°£ À̳»
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 4½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : 6-12½Ã°£
- Èí¼ö : °æ±¸ : 60-80%
- ¼Ò½Ç : ¹Ìº¯Èü·Î ½Å¹è¼³µÈ´Ù.
|
| Biotransformation |
Hydrochlorothiazide¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hydrochlorothiazide is not metabolized.
Triamterene¿¡ ´ëÇÑ Biotransformation Á¤º¸ Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.
|
| Toxicity |
Hydrochlorothiazide¿¡ ´ëÇÑ Toxicity Á¤º¸ The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.
Triamterene¿¡ ´ëÇÑ Toxicity Á¤º¸ In the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD50 in mice is 380 mg/kg.
|
| Drug Interactions |
Hydrochlorothiazide¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Amantadine The diuretic increases the adverse effect of amantadineDeslanoside Possible electrolyte variations and arrhythmiasDigitoxin Possible electrolyte variations and arrhythmiasDigoxin Possible electrolyte variations and arrhythmiasLithium The thiazide diuretic increases serum levels of lithiumDofetilide Increased risk of cardiotoxicity and arrhythmiasDiazoxide Significant hyperglycemic effect
Triamterene¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Hydrochlorothiazide¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Avoid excess salt/sodium unless otherwise instructed by your physician.Take with food.Increase potassium intake; add a banana or orange juice; unless instructed otherwise.Avoid natural licorice.Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
|
| Drug Target |
[Drug Target]
|
| Description |
Hydrochlorothiazide¿¡ ´ëÇÑ Description Á¤º¸ A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. [PubChem]
Triamterene¿¡ ´ëÇÑ Description Á¤º¸ A pteridine that is used as a mild diuretic. [PubChem]
|
| Dosage Form |
Triamterene¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule Oral
|
| Drug Category |
Hydrochlorothiazide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypertensive AgentsDiureticsSodium Chloride Symporter Inhibitors
Triamterene¿¡ ´ëÇÑ Drug_Category Á¤º¸ DiureticsPotassium-sparing Diuretics
|
| Smiles String Canonical |
Hydrochlorothiazide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Triamterene¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC1=NC(N)=C2N=C(C3=CC=CC=C3)C(N)=NC2=N1
|
| Smiles String Isomeric |
Hydrochlorothiazide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Triamterene¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC1=NC(N)=C2N=C(C3=CC=CC=C3)C(N)=NC2=N1
|
| InChI Identifier |
Hydrochlorothiazide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)/f/h9H2
Triamterene¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)/f/h13-15H2
|
| Chemical IUPAC Name |
Hydrochlorothiazide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 6-chloro-1,1-dioxo-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide
Triamterene¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 6-phenylpteridine-2,4,7-triamine
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2017-08-01
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|